BRPI0418805A - construção de recombinante de adenovìrus oncolìtico expressando especificamente um fator imunomodulatório gm-csf em células tumorais e seus usos - Google Patents

construção de recombinante de adenovìrus oncolìtico expressando especificamente um fator imunomodulatório gm-csf em células tumorais e seus usos

Info

Publication number
BRPI0418805A
BRPI0418805A BRPI0418805-5A BRPI0418805A BRPI0418805A BR PI0418805 A BRPI0418805 A BR PI0418805A BR PI0418805 A BRPI0418805 A BR PI0418805A BR PI0418805 A BRPI0418805 A BR PI0418805A
Authority
BR
Brazil
Prior art keywords
csf
tumor cells
oncolytic adenovirus
immunomodulatory factor
specifically expressing
Prior art date
Application number
BRPI0418805-5A
Other languages
English (en)
Inventor
Zunhong Ke
Original Assignee
Chengdu Kanghong Biotechnologi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chengdu Kanghong Biotechnologi filed Critical Chengdu Kanghong Biotechnologi
Publication of BRPI0418805A publication Critical patent/BRPI0418805A/pt
Publication of BRPI0418805B1 publication Critical patent/BRPI0418805B1/pt
Publication of BRPI0418805B8 publication Critical patent/BRPI0418805B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60—Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6009—Vectors comprising as targeting moiety peptide derived from defined protein from viruses dsDNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/36—Vector systems having a special element relevant for transcription being a transcription termination element
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

CONSTRUçãO DE RECOMBINANTE DE ADENOVìRUS ONCOLìTICO EXPRESSANDO ESPECIFICAMENTE UM FATOR IMUNOMODULATóRIO GM-CSF EM CéLULAS TUMORAIS E SEUS USOS . A presente invenção relaciona-se à terapia do gene para tumores, especificamente, a terapia relaciona-se à construção do adenovírus oncolítico recombinado, que expressa especificamente um fator imunomodulatório GM-CSF em células tumorais e seus usos.
BRPI0418805A 2004-06-07 2004-11-19 construção de recombinante de adenovírus oncolítico expressando especificamente um fator imunomodulatório gmcsf em células tumorais e seus usos BRPI0418805B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNB200410046237XA CN100361710C (zh) 2004-06-07 2004-06-07 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用
CN200410046237.X 2004-06-07
PCT/CN2004/001321 WO2005121343A1 (en) 2004-06-07 2004-11-19 Construction of oncolytic adenovirus recombinant specifically expressing immune modulatory factor gm-csf in tumor cells and uses thereof

Publications (3)

Publication Number Publication Date
BRPI0418805A true BRPI0418805A (pt) 2007-10-16
BRPI0418805B1 BRPI0418805B1 (pt) 2021-01-26
BRPI0418805B8 BRPI0418805B8 (pt) 2021-05-25

Family

ID=35503069

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0418805A BRPI0418805B8 (pt) 2004-06-07 2004-11-19 construção de recombinante de adenovírus oncolítico expressando especificamente um fator imunomodulatório gmcsf em células tumorais e seus usos

Country Status (12)

Country Link
US (1) US7951585B2 (pt)
EP (1) EP1767642B1 (pt)
JP (1) JP4874247B2 (pt)
CN (1) CN100361710C (pt)
BR (1) BRPI0418805B8 (pt)
CA (1) CA2568995C (pt)
DK (1) DK1767642T3 (pt)
ES (1) ES2466415T3 (pt)
PL (1) PL1767642T3 (pt)
PT (1) PT1767642E (pt)
RU (1) RU2361611C2 (pt)
WO (1) WO2005121343A1 (pt)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006079169A1 (en) * 2005-01-25 2006-08-03 Apollo Life Sciences Limited Parameter selected gm-csf, il-3, il-4, il-5 and chimeras thereof for therapeutic and diagnostic purposes
ES2633574T3 (es) 2005-03-25 2017-09-22 Regeneron Pharmaceuticals, Inc. Formulaciones de antagonistas de VEGF
CA2654510C (en) 2006-06-16 2015-03-17 Regeneron Pharmaceuticals, Inc. Vegf antagonist formulations suitable for intravitreal administration
JP2008048621A (ja) * 2006-08-22 2008-03-06 Chiba Prefecture キメラ型アデノウイルスとその作製方法並びにそれを用いた医薬
CN101391104B (zh) * 2007-09-21 2010-10-06 成都康弘生物科技有限公司 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的新用途
US20130323205A1 (en) 2010-09-24 2013-12-05 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
CA2860170C (en) 2010-12-22 2022-06-14 The Board Of Trustees Of The Leland Stanford Junior University Superagonists and antagonists of interleukin-2
KR20190049934A (ko) 2011-01-13 2019-05-09 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
CN102174479B (zh) * 2011-03-02 2013-04-03 北京锤特生物科技有限公司 靶向性治疗人肿瘤的溶肿瘤腺病毒及其应用
US9624476B2 (en) 2011-08-23 2017-04-18 National Institute Of Biomedical Innovation Conditionally replicating adenovirus
AU2012298013B2 (en) * 2011-08-23 2015-09-24 National Institute Of Biomedical Innovation Conditionally replicating adenovirus
FI123955B (en) 2011-11-25 2014-01-15 Oncos Therapeutics Ltd Oncolytic adenovirus
EP2825889A4 (en) * 2012-03-14 2015-10-28 Salk Inst For Biological Studi ADENOVIRAL TUMOR DIAGNOSIS
US9017672B2 (en) 2012-05-11 2015-04-28 Immunicum Aktiebolag Hexon Tat-PTD modified adenovirus and uses thereof
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
BR112015024605A2 (pt) * 2013-03-24 2017-07-18 Oisin Biotechnologies sistemas e métodos para a produção visada de proteína terapêutica dentro de célula alvo
JP6396891B2 (ja) 2013-04-17 2018-09-26 新日本製薬株式会社 遺伝子改変コクサッキーウイルス
HUE035875T2 (hu) 2013-10-25 2018-06-28 Psioxus Therapeutics Ltd Heterológ géneket tartalmazó onkolitikus adenovírusok
WO2015080631A1 (en) * 2013-11-27 2015-06-04 Obschestvo S Ogranichennoy Otvetstvennost`Yu "Panacela Labs" Improved expression vector for toll-like receptor and agonist and use for treating cancer
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
KR102608590B1 (ko) 2014-09-24 2023-12-01 솔크 인스티튜트 포 바이올로지칼 스터디즈 종양 살상 바이러스 및 이의 사용방법
HRP20200439T1 (hr) 2015-04-30 2020-06-12 Psioxus Therapeutics Limited Onkolitički adenovirus koji kodira protein b7
BR112018012180A2 (pt) 2015-12-17 2018-12-04 Psioxus Therapeutics Ltd vírus de codificação de um anticorpo ou fragmento de complexo anti-tcr
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
WO2017147269A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
IL303187A (en) 2016-08-29 2023-07-01 Akamis Bio Ltd Adenovirus with bispecific T cell activator
EP3532082A4 (en) 2016-12-12 2020-08-26 Salk Institute for Biological Studies SYNTHETIC ADENOVIRUS TUMOR TARGETING AND THEIR USES
JP2020503390A (ja) 2017-01-09 2020-01-30 オイシン バイオテクノロジーズ， インコーポレイテッド 治療用タンパク質の標的細胞特異的な産生のため、および標的細胞に関連する疾患、状態、または障害の治療のための、膜融合性脂質ナノ粒子、ならびにその作製および使用のための方法
CN111201035A (zh) 2017-06-19 2020-05-26 梅迪塞纳医疗股份有限公司 Il-2超激动剂、激动剂及其融合体的用途和方法
HUE059827T2 (hu) 2017-11-30 2023-01-28 Regeneron Pharma VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére
CN111630159A (zh) * 2017-12-13 2020-09-04 基因药物株式会社 重组腺病毒及包含此病毒的干细胞
CN112292449A (zh) 2018-04-09 2021-01-29 萨克生物研究学院 具有增强的复制特性的溶瘤腺病毒组合物
CN112312918A (zh) 2018-04-18 2021-02-02 奥依信生物技术公司 促融合脂质纳米粒和制备其的方法以及其用于靶细胞特异性产生治疗蛋白和治疗与靶细胞有关的疾病、病况或障碍的用途
EP4079750A3 (en) 2018-11-21 2023-01-04 Mayo Foundation for Medical Education and Research Adenoviruses and methods for using adenoviruses
JP7508109B2 (ja) * 2019-02-12 2024-07-01 国立大学法人大阪大学 ヒト３５型アデノウイルスを基盤とした腫瘍溶解性ウイルス
CN113710694A (zh) 2019-04-29 2021-11-26 梅奥医学教育及研究基金会 用于治疗癌症的多价pd-l1结合化合物
CN120060368A (zh) * 2020-03-23 2025-05-30 株式会社库利金 包含双特异性核酸分子的溶瘤病毒的结构
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
RU2753742C1 (ru) * 2020-10-16 2021-08-24 Федеральное государственное автономное образовательное учреждение высшего образования "Новосибирский национальный исследовательский государственный университет" (Новосибирский государственный университет, НГУ) Рекомбинантный штамм Ad6-hTERT-GMCSF, содержащий встройку промотора теломеразы человека hTERT, а также гена гранулоцитарно-макрофагального колониестимулирующего фактора человека, обладающий избирательной цитолитической активностью против теломераза-положительных опухолевых клеток и экспрессирующий активный человеческий гранулоцитарно-макрофагальный колониестимулирующий фактор
CN115029325A (zh) * 2021-03-08 2022-09-09 南京惟亚德生物医药有限公司 一种重组溶瘤腺病毒及其应用
CN113444730A (zh) * 2021-03-17 2021-09-28 昆明市延安医院 一种原发性肝细胞klotho基因转导干细胞筛选构建方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7592317B1 (en) * 1994-08-11 2009-09-22 The University Of Chicago Constitutive gene expression in conjuction with ionizing radiation
WO1996009399A2 (en) 1994-09-23 1996-03-28 Somatix Therapy Corporation Chimeric adenovirus for gene delivery
US6020191A (en) 1997-04-14 2000-02-01 Genzyme Corporation Adenoviral vectors capable of facilitating increased persistence of transgene expression
US5891432A (en) * 1997-07-29 1999-04-06 The Immune Response Corporation Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
US6348450B1 (en) 1997-08-13 2002-02-19 The Uab Research Foundation Noninvasive genetic immunization, expression products therefrom and uses thereof
WO1999046371A2 (en) 1998-03-11 1999-09-16 Board Of Regents, The University Of Texas System Induction of apoptotic or cytotoxic gene expression by adenoviral mediated gene codelivery
AU772963B2 (en) * 1998-04-24 2004-05-13 Onyx Pharmaceuticals Adenoviral vectors for treating disease
US6627190B2 (en) 1999-07-12 2003-09-30 Saint Louis University Recombinant adenovirus vectors that are replication-competent in tert-expressing cells
GB9916851D0 (en) * 1999-07-20 1999-09-22 Univ Wales Bangor Manipulation of particles in liquid media
CN1382218A (zh) 1999-11-15 2002-11-27 昂尼克斯药物公司 溶瘤腺病毒
WO2002012523A2 (en) * 2000-08-10 2002-02-14 Crucell Holland B.V. Transduction of chondrocytes using adenoviral vectors
AU2002235141A1 (en) 2000-11-27 2002-06-03 Geron Corporation Glycosyltransferase vectors for treating cancer
IL152420A0 (en) * 2001-02-23 2003-05-29 Novartis Ag Novel oncolytic adenoviral vectors
CN1177053C (zh) * 2001-04-13 2004-11-24 上海华康生物技术有限公司 靶向性、高表达人粒细胞巨噬细胞集落刺激因子的重组腺病毒及其制法和用途
US6905678B2 (en) * 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
CN1195056C (zh) * 2001-07-12 2005-03-30 钱其军 一种在肿瘤细胞中特异性增殖及高效表达抗癌基因的重组病毒及其构建方法
US20030099616A1 (en) * 2001-07-25 2003-05-29 Irving John M. Dual specificity tumor killing vectors driven by the telomerase promoter
EP1420803A1 (en) 2001-08-08 2004-05-26 Board Of Regents, The University Of Texas System Method for amplifying expression from a cell specific promoter
JP3867968B2 (ja) * 2002-07-08 2007-01-17 関西ティー・エル・オー株式会社 腫瘍細胞において選択的に増殖する腫瘍融解ウイルス
CN1259106C (zh) * 2002-12-23 2006-06-14 中国科学院上海生命科学研究院 一种抗癌靶向基因病毒药物的制备方法
ES2292271B1 (es) 2004-05-20 2009-02-16 Proyecto De Biomedicina Cima, S.L. Un vector hibrido adenovirus-alfavirus para la administracion eficaz y expresion de genes terapeuticos en celulas tumorales.

Also Published As

Publication number Publication date
EP1767642A1 (en) 2007-03-28
PL1767642T3 (pl) 2014-08-29
CA2568995A1 (en) 2005-12-22
RU2361611C2 (ru) 2009-07-20
JP2008501349A (ja) 2008-01-24
US7951585B2 (en) 2011-05-31
BRPI0418805B8 (pt) 2021-05-25
BRPI0418805B1 (pt) 2021-01-26
WO2005121343A1 (en) 2005-12-22
RU2006146665A (ru) 2008-07-20
PT1767642E (pt) 2014-06-03
CN100361710C (zh) 2008-01-16
EP1767642B1 (en) 2014-04-23
CA2568995C (en) 2012-02-21
ES2466415T3 (es) 2014-06-10
DK1767642T3 (da) 2014-05-26
JP4874247B2 (ja) 2012-02-15
CA2568995E (en) 2005-12-22
CN1706955A (zh) 2005-12-14
EP1767642A4 (en) 2008-06-25
US20100047208A1 (en) 2010-02-25

Similar Documents

Publication Publication Date Title
BRPI0418805A (pt) construção de recombinante de adenovìrus oncolìtico expressando especificamente um fator imunomodulatório gm-csf em células tumorais e seus usos
NI200800193A (es) Anticuerpos humanos anti-il-23, composiciones, métodos y usos.
MX2013012167A (es) Estratificaciones a base de bcma y terapia para pacientes con mieloma multiple.
CY1122654T1 (el) Ενωσεις για βελτιωμενη iiκη μεταγωγη
BRPI0510475B8 (pt) adenovírus quimérico recombinante, uso do mesmo no tratamento de câncer e métodos de inibição de crescimento de uma célula de câncer, de fornecimento de uma proteína terapêutica a uma célula e para o isolamento do adenovírus
BR112013000650A2 (pt) poliptídeos de fator ix e métodos de uso dos mesmos.
MX2019009191A (es) Proteinas de fusion de enzima lisosomal terapeutica objetivo y uso de las mismas.
EP4523696A3 (en) Enhanced adoptive cell therapy
GT201200189A (es) Antagonistas de pcsk9
PL1773816T3 (pl) Modulatory transporterów posiadających kasetę wiążącą ATP
MX2012004868A (es) Proteinas de enlace al antigeno il-23 humanas.
DOP2015000050A (es) Polipéptidos que contienen fc con glicosilación alterada y función efectora reducida
BR112013010834A2 (pt) polipeptídeos fator ix modificados e usos dos mesmos
WO2012112544A3 (en) Humanized m-csf mice
MX2017008817A (es) Composiciones y metodos para la glicosilacion de proteinas.
ME01327B (me) Humana antitela visokog afiniteta prema pcsk9
MX369149B (es) Construcciones de anticuerpos para cdh19 y cd3.
ATE485066T1 (de) Medizinische ballons mit modifizierten oberflächen
UY31073A1 (es) Inhibidores de la proteína activadora de la 5-lipoxigenasa (flap)
WO2008106646A3 (en) Methods and formulations for topical gene therapy
EP3799871A3 (en) Pyrazol-3-ones that activate pro-apototic bax
ITBO20080047A1 (it) Azionamento elettrico e metodo di pilotaggio dello stesso.
MX2010003110A (es) Composiciones de polipeptido de elemento nuclear intercalado largo y metodos de uso de las mismas.
BR112022005963A2 (pt) Células com expressão de transgenes sustentada
HN2006009000A (es) Formas farmaceuticas con propiedades farmacocineticas mejoradas

Legal Events

Date Code Title Description
B06G Technical and formal requirements: other requirements [chapter 6.7 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notice of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal: appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 26/01/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 19/11/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF